Calliditas Therapeutics presents data from the NefIgArd Phase 3 trial

Calliditas Therapeutics announced the presentations of new biomarker and subgroup analyses from the Phase 3 NefIgArd study with Nefecon in adults with Primary IgA nephropathy. The data was presented in both posters and oral presentations at the 17th International Symposium on IgA Nephropathy, held in Tokyo, Japan, on September 25-27, 2023. “We are proud to have showcased new data at this year’s International Symposium on IgAN in Tokyo,” said Richard Phillipson, Chief Medical Officer at Calliditas. “Taken together, the positive findings from our biomarker and patient subgroup analyses from our Phase 3 NefIgArd study indicate that Nefecon treatment results in a coordinated immunological response with the potential to modulate the intestinal immune network responsible for IgA production. These additional findings further reinforce the potential of TARPEYO in enabling physicians to proactively manage and potentially mitigate the impact of the disease by targeting the source and slowing kidney function decline.”